BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9726093)

  • 1. Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials.
    Goldberg RM; Erlichman C
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):59-63. PubMed ID: 9726093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European experience with irinotecan plus fluorouracil/folinic acid or mitomycin.
    Khayat D; Gil-Delgado M; Antoine EC; Coeffic D; Benhammouda A; Grapin JP; Bastian G
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):64-7. PubMed ID: 9726094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
    Saltz LB; Douillard JY; Pirotta N; Alakl M; Gruia G; Awad L; Elfring GL; Locker PK; Miller LL
    Oncologist; 2001; 6(1):81-91. PubMed ID: 11161231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
    Grem JL
    Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-8-S18-18. PubMed ID: 9420016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective comparison of single-agent chemotherapy with weekly 5-fluorouracil or weekly irinotecan in previously treated patients with metastatic colorectal cancer.
    Lavrenkov K; Man S; Mermershtain W; Cohen Y
    J Chemother; 2002 Feb; 14(1):84-7. PubMed ID: 11892905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan: toward clinical end points in drug development.
    Pazdur R
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irinotecan as first-line treatment of colorectal cancer: new indication. A modest advantage.
    Prescrire Int; 2001 Apr; 10(52):41-3. PubMed ID: 11718156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the use of irinotecan in colorectal cancer.
    Cunningham D; Maroun J; Vanhoefer U; Van Cutsem E
    Oncologist; 2001; 6 Suppl 4():17-23. PubMed ID: 11585970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Van Cutsem E; Blijham GH
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
    Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. North Central Cancer Treatment Group--Mayo Clinic trials in colon cancer.
    O'Connell MJ
    Semin Oncol; 2001 Feb; 28(1 Suppl 1):4-8. PubMed ID: 11273589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irinotecan in the treatment of colorectal cancer: clinical overview.
    Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
    J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer.
    Grivicich I; Mans DR; Peters GJ; Schwartsmann G
    Braz J Med Biol Res; 2001 Sep; 34(9):1087-103. PubMed ID: 11514832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival.
    Zaniboni A
    J Clin Oncol; 1997 Jun; 15(6):2432-41. PubMed ID: 9196159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on European adjuvant trials with irinotecan for colorectal cancer.
    Douillard JY; Barbarot V; Bennouna J
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):13-5. PubMed ID: 12014862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recent advance in chemotherapy for advanced colorectal cancer].
    Aiba K
    Gan To Kagaku Ryoho; 1996 Apr; 23(5):535-48. PubMed ID: 8678510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US pivotal studies of irinotecan in colorectal carcinoma.
    Pitot HC
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):48-53. PubMed ID: 9726091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorouracil-based combinations in the treatment of metastatic breast cancer.
    Klaassen U; Wilke H; Harstrick A; Seeber S
    Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):31-5. PubMed ID: 9516601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer.
    Khayat D; Gil-Delgado M; Antoine EC; Nizri D; Bastian G
    Oncology (Williston Park); 2001 Apr; 15(4):415-29; discussion 429-30, 433-4. PubMed ID: 11346931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and toxicity of irinotecan in patients with colorectal cancer.
    Rothenberg ML
    Semin Oncol; 1998 Oct; 25(5 Suppl 11):39-46. PubMed ID: 9786315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.